Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 1998 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00002455
First received: November 1, 1999
Last updated: August 6, 2013
Last verified: November 1998
  Purpose

RATIONALE: Immunotherapy uses different ways to stimulate the immune system and stop cancer cells from growing. Immunotherapy biological extracts may be useful as adjuvant therapy in treating patients who have had surgery for breast cancer, colon cancer, or melanoma.

PURPOSE: Phase III trial to study the effectiveness of Corynebacterium granulosum extract as maintenance immunotherapy following surgery in treating patients with breast cancer, colon cancer, or melanoma.


Condition Intervention Phase
Breast Cancer
Colorectal Cancer
Melanoma (Skin)
Biological: Corynebacterium granulosum P40
Procedure: adjuvant therapy
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Recurrence [ Designated as safety issue: No ]
  • Response to study parameters [ Designated as safety issue: No ]
  • Survival rate [ Designated as safety issue: No ]

Study Start Date: April 1971
Detailed Description:

OBJECTIVES:

  • Determine the survival of patients with colon cancer, breast cancer, or melanoma with minimal residual disease after surgical resection treated with maintenance immunotherapy using Corynebacterium granulosum P40.
  • Determine leucocyte adherence inhibition, an indication of metastases, over time in patients treated with this regimen.

OUTLINE: This is a multicenter study. Patients are stratified by center and are matched with case-controls by disease type and stage.

Beginning 2 weeks after surgical resection, patients receive Corynebacterium granulosum P40 subcutaneously weekly for 6 weeks, followed by rest for 3 months. Treatment continues for life.

Patients are followed for survival.

PROJECTED ACCRUAL: Not specified

  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of colon cancer, breast cancer, or melanoma with minimal residual disease (at least 90% of tumor mass resected) after surgical resection
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age:

  • 20 to 80

Sex:

  • Not specified

Menopausal status:

  • Not specified

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • Not specified

Renal:

  • Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002455

Locations
Argentina
Centro Oncologico de Excelencia
Gonnet, Buenos Aires, Argentina, 1987 MB
Sponsors and Collaborators
Centro Oncologico de Excelencia
Investigators
Study Chair: Hugo Omar De Carli, MD Centro Oncologico de Excelencia
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00002455     History of Changes
Other Study ID Numbers: ARG-CO/BR-1, CDR0000072435
Study First Received: November 1, 1999
Last Updated: August 6, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage I colon cancer
stage II colon cancer
stage III colon cancer
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer
recurrent breast cancer
recurrent colon cancer
stage I melanoma
stage II melanoma
stage III melanoma
recurrent melanoma

Additional relevant MeSH terms:
Breast Neoplasms
Colonic Neoplasms
Colorectal Neoplasms
Melanoma
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on July 29, 2014